- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Diplomat becomes distributor of recently approved cancer drug
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PITTSBURGH — The Food and Drug Administration has approved a drug for epilepsy made by Mylan, the drug maker said.
The FDA approved Mylan's levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.
The drug is a generic version of UCB's Keppra XR, used to treat partial onset seizures in epilepsy patients ages 16 years and older.
Various versions of the drug had sales of about $162.8 million during the 12-month period ended in September, according to IMS Health.